Allena Pharmaceuticals to Participate Virtually in Upcoming Investor Conferences in November
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced participation in three investor conferences in November, focusing on their innovative oral enzyme therapeutics for metabolic and kidney disorders.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) announced participation in three investor conferences in November, focusing on their innovative oral enzyme therapeutics for metabolic and kidney disorders. The events include the 29th Annual Credit Suisse Virtual Healthcare Conference on November 10 at 1:15 p.m. ET, the H.C. Wainwright & Co. 6th Annual Israel Conference on November 12 at 11:00 a.m. ET, and the Jefferies Virtual London Healthcare Conference from November 17-19, with one-on-one meetings available. Live audio webcasts can be accessed on their website.
Details
News Market Reaction – ALNA
The recorded move for ALNA in the trading session of this news was +3.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in three upcoming investor conferences in November:
29th Annual Credit Suisse Virtual Healthcare Conference
Date: Tuesday, November 10
Presentation Time: 1:15 p.m. ET
H.C. Wainwright & Co. 6th Annual Israel Conference
Date: Thursday, November 12
Presentation Time: 11:00 a.m. ET
Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17- Thursday, November 19
Management will be available for one-on-one meetings.
Live audio webcasts of the Credit Suisse and H.C. Wainwright presentations will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. Replays of the webcasts will be available on the Allena website for 30 days following each presentation.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.